Ra Medical Systems, Inc.
Ra Medical Systems, Inc. RMED Peers
See (RMED) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RMED | $0.59 | +10.00% | 3.8M | -0.02 | -$35.78 | N/A |
| ABT | $133.55 | -0.29% | 232.4B | 17.34 | $7.70 | +1.71% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $102.04 | -0.77% | 151B | 74.48 | $1.37 | N/A |
| SYK | $384.07 | +0.25% | 146.8B | 51.97 | $7.39 | +0.85% |
| MDT | $87.38 | +0.44% | 112.1B | 24.20 | $3.61 | +3.21% |
| EW | $77.52 | -0.32% | 45.5B | 32.03 | $2.42 | N/A |
| DXCM | $86.67 | +1.08% | 34B | 65.17 | $1.33 | N/A |
| STE | $243.73 | +0.06% | 24B | 39.63 | $6.15 | +0.92% |
| PODD | $311.77 | -1.70% | 21.9B | 56.07 | $5.56 | N/A |
Stock Comparison
RMED vs ABT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ABT has a market cap of 232.4B. Regarding current trading prices, RMED is priced at $0.59, while ABT trades at $133.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ABT's P/E ratio is 17.34. In terms of profitability, RMED's ROE is +3.12%, compared to ABT's ROE of +0.31%. Regarding short-term risk, RMED is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BSX-PA Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RMED is priced at $0.59, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RMED's ROE is +3.12%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, RMED is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BSX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BSX has a market cap of 151B. Regarding current trading prices, RMED is priced at $0.59, while BSX trades at $102.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BSX's P/E ratio is 74.48. In terms of profitability, RMED's ROE is +3.12%, compared to BSX's ROE of +0.10%. Regarding short-term risk, RMED is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SYK Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SYK has a market cap of 146.8B. Regarding current trading prices, RMED is priced at $0.59, while SYK trades at $384.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SYK's P/E ratio is 51.97. In terms of profitability, RMED's ROE is +3.12%, compared to SYK's ROE of +0.11%. Regarding short-term risk, RMED is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs MDT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, MDT has a market cap of 112.1B. Regarding current trading prices, RMED is priced at $0.59, while MDT trades at $87.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas MDT's P/E ratio is 24.20. In terms of profitability, RMED's ROE is +3.12%, compared to MDT's ROE of +0.09%. Regarding short-term risk, RMED is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs EW Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, EW has a market cap of 45.5B. Regarding current trading prices, RMED is priced at $0.59, while EW trades at $77.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas EW's P/E ratio is 32.03. In terms of profitability, RMED's ROE is +3.12%, compared to EW's ROE of +0.49%. Regarding short-term risk, RMED is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs DXCM Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, DXCM has a market cap of 34B. Regarding current trading prices, RMED is priced at $0.59, while DXCM trades at $86.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas DXCM's P/E ratio is 65.17. In terms of profitability, RMED's ROE is +3.12%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, RMED is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs STE Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, STE has a market cap of 24B. Regarding current trading prices, RMED is priced at $0.59, while STE trades at $243.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas STE's P/E ratio is 39.63. In terms of profitability, RMED's ROE is +3.12%, compared to STE's ROE of +0.09%. Regarding short-term risk, RMED is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs PODD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, PODD has a market cap of 21.9B. Regarding current trading prices, RMED is priced at $0.59, while PODD trades at $311.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas PODD's P/E ratio is 56.07. In terms of profitability, RMED's ROE is +3.12%, compared to PODD's ROE of +0.35%. Regarding short-term risk, RMED is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs PHG Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, PHG has a market cap of 21.7B. Regarding current trading prices, RMED is priced at $0.59, while PHG trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas PHG's P/E ratio is 78.20. In terms of profitability, RMED's ROE is +3.12%, compared to PHG's ROE of +0.03%. Regarding short-term risk, RMED is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ZBH Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ZBH has a market cap of 18.3B. Regarding current trading prices, RMED is priced at $0.59, while ZBH trades at $92.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ZBH's P/E ratio is 20.53. In terms of profitability, RMED's ROE is +3.12%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, RMED is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ABMD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RMED is priced at $0.59, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RMED's ROE is +3.12%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RMED is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SNN Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SNN has a market cap of 13.2B. Regarding current trading prices, RMED is priced at $0.59, while SNN trades at $30.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SNN's P/E ratio is 32.18. In terms of profitability, RMED's ROE is +3.12%, compared to SNN's ROE of +0.08%. Regarding short-term risk, RMED is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ALGN Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ALGN has a market cap of 13.1B. Regarding current trading prices, RMED is priced at $0.59, while ALGN trades at $180.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ALGN's P/E ratio is 32.84. In terms of profitability, RMED's ROE is +3.12%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, RMED is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SWAV Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RMED is priced at $0.59, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RMED's ROE is +3.12%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, RMED is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs PEN Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, PEN has a market cap of 10B. Regarding current trading prices, RMED is priced at $0.59, while PEN trades at $259.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas PEN's P/E ratio is 242.09. In terms of profitability, RMED's ROE is +3.12%, compared to PEN's ROE of +0.04%. Regarding short-term risk, RMED is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs GMED Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, GMED has a market cap of 8.1B. Regarding current trading prices, RMED is priced at $0.59, while GMED trades at $59.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas GMED's P/E ratio is 44.69. In terms of profitability, RMED's ROE is +3.12%, compared to GMED's ROE of +0.05%. Regarding short-term risk, RMED is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BIO-B Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BIO-B has a market cap of 6.7B. Regarding current trading prices, RMED is priced at $0.59, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, RMED's ROE is +3.12%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, RMED is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BIO Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BIO has a market cap of 6B. Regarding current trading prices, RMED is priced at $0.59, while BIO trades at $219.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BIO's P/E ratio is -2.87. In terms of profitability, RMED's ROE is +3.12%, compared to BIO's ROE of -0.32%. Regarding short-term risk, RMED is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BRKR Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BRKR has a market cap of 5.8B. Regarding current trading prices, RMED is priced at $0.59, while BRKR trades at $38.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BRKR's P/E ratio is 73.65. In terms of profitability, RMED's ROE is +3.12%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, RMED is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs GKOS Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, GKOS has a market cap of 5.3B. Regarding current trading prices, RMED is priced at $0.59, while GKOS trades at $93.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas GKOS's P/E ratio is -40.97. In terms of profitability, RMED's ROE is +3.12%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, RMED is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs TMDX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, TMDX has a market cap of 4.7B. Regarding current trading prices, RMED is priced at $0.59, while TMDX trades at $139.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas TMDX's P/E ratio is 97.92. In terms of profitability, RMED's ROE is +3.12%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, RMED is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs NARI Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RMED is priced at $0.59, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas NARI's P/E ratio is -59.24. In terms of profitability, RMED's ROE is +3.12%, compared to NARI's ROE of -0.18%. Regarding short-term risk, RMED is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs IRTC Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, IRTC has a market cap of 4.7B. Regarding current trading prices, RMED is priced at $0.59, while IRTC trades at $146.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas IRTC's P/E ratio is -46.86. In terms of profitability, RMED's ROE is +3.12%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, RMED is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ITGR Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, RMED is priced at $0.59, while ITGR trades at $121.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ITGR's P/E ratio is 56.42. In terms of profitability, RMED's ROE is +3.12%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, RMED is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs INSP Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, INSP has a market cap of 4B. Regarding current trading prices, RMED is priced at $0.59, while INSP trades at $135.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas INSP's P/E ratio is 62.07. In terms of profitability, RMED's ROE is +3.12%, compared to INSP's ROE of +0.10%. Regarding short-term risk, RMED is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs AXNX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RMED is priced at $0.59, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RMED's ROE is +3.12%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RMED is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs PRCT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, PRCT has a market cap of 3.5B. Regarding current trading prices, RMED is priced at $0.59, while PRCT trades at $62.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas PRCT's P/E ratio is -36.13. In terms of profitability, RMED's ROE is +3.12%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, RMED is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs LIVN Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, RMED is priced at $0.59, while LIVN trades at $45.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas LIVN's P/E ratio is -11.29. In terms of profitability, RMED's ROE is +3.12%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, RMED is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs NUVA Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RMED is priced at $0.59, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RMED's ROE is +3.12%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RMED is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ATEC Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ATEC has a market cap of 1.9B. Regarding current trading prices, RMED is priced at $0.59, while ATEC trades at $12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ATEC's P/E ratio is -11.17. In terms of profitability, RMED's ROE is +3.12%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, RMED is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs UFPT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, RMED is priced at $0.59, while UFPT trades at $237.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas UFPT's P/E ratio is 29.14. In terms of profitability, RMED's ROE is +3.12%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, RMED is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs CNMD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, CNMD has a market cap of 1.8B. Regarding current trading prices, RMED is priced at $0.59, while CNMD trades at $56.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas CNMD's P/E ratio is 14.94. In terms of profitability, RMED's ROE is +3.12%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, RMED is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs TNDM Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, RMED is priced at $0.59, while TNDM trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas TNDM's P/E ratio is -7.45. In terms of profitability, RMED's ROE is +3.12%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, RMED is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs HSKA Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RMED is priced at $0.59, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RMED's ROE is +3.12%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RMED is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SSII Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SSII has a market cap of 1.2B. Regarding current trading prices, RMED is priced at $0.59, while SSII trades at $6.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SSII's P/E ratio is -76.62. In terms of profitability, RMED's ROE is +3.12%, compared to SSII's ROE of -1.33%. Regarding short-term risk, RMED is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs AORT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, RMED is priced at $0.59, while AORT trades at $28.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas AORT's P/E ratio is -56.75. In terms of profitability, RMED's ROE is +3.12%, compared to AORT's ROE of -0.07%. Regarding short-term risk, RMED is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs AHCO Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, RMED is priced at $0.59, while AHCO trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas AHCO's P/E ratio is 15.34. In terms of profitability, RMED's ROE is +3.12%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, RMED is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SILK Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RMED is priced at $0.59, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SILK's P/E ratio is -18.96. In terms of profitability, RMED's ROE is +3.12%, compared to SILK's ROE of -0.29%. Regarding short-term risk, RMED is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs FNA Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RMED is priced at $0.59, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas FNA's P/E ratio is -19.83. In terms of profitability, RMED's ROE is +3.12%, compared to FNA's ROE of -0.36%. Regarding short-term risk, RMED is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ESTA Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ESTA has a market cap of 1.1B. Regarding current trading prices, RMED is priced at $0.59, while ESTA trades at $37.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ESTA's P/E ratio is -12.18. In terms of profitability, RMED's ROE is +3.12%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, RMED is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs IART Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, RMED is priced at $0.59, while IART trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas IART's P/E ratio is -35.68. In terms of profitability, RMED's ROE is +3.12%, compared to IART's ROE of -0.03%. Regarding short-term risk, RMED is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs INMD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, INMD has a market cap of 985M. Regarding current trading prices, RMED is priced at $0.59, while INMD trades at $14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas INMD's P/E ratio is 6.35. In terms of profitability, RMED's ROE is +3.12%, compared to INMD's ROE of +0.25%. Regarding short-term risk, RMED is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs CSII Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RMED is priced at $0.59, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas CSII's P/E ratio is -20.83. In terms of profitability, RMED's ROE is +3.12%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RMED is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SIBN Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SIBN has a market cap of 805.4M. Regarding current trading prices, RMED is priced at $0.59, while SIBN trades at $18.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SIBN's P/E ratio is -30.00. In terms of profitability, RMED's ROE is +3.12%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, RMED is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs IRMD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, IRMD has a market cap of 765.6M. Regarding current trading prices, RMED is priced at $0.59, while IRMD trades at $60.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas IRMD's P/E ratio is 38.85. In terms of profitability, RMED's ROE is +3.12%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, RMED is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs CRY Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, RMED is priced at $0.59, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas CRY's P/E ratio is 425.71. In terms of profitability, RMED's ROE is +3.12%, compared to CRY's ROE of -0.07%. Regarding short-term risk, RMED is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs CBLL Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, CBLL has a market cap of 646.6M. Regarding current trading prices, RMED is priced at $0.59, while CBLL trades at $17.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas CBLL's P/E ratio is -14.31. In terms of profitability, RMED's ROE is +3.12%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, RMED is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BFLY Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BFLY has a market cap of 613.3M. Regarding current trading prices, RMED is priced at $0.59, while BFLY trades at $2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BFLY's P/E ratio is -8.25. In terms of profitability, RMED's ROE is +3.12%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, RMED is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs RXST Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, RXST has a market cap of 611.2M. Regarding current trading prices, RMED is priced at $0.59, while RXST trades at $15.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas RXST's P/E ratio is -22.79. In terms of profitability, RMED's ROE is +3.12%, compared to RXST's ROE of -0.10%. Regarding short-term risk, RMED is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BFLY-WT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BFLY-WT has a market cap of 605.9M. Regarding current trading prices, RMED is priced at $0.59, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, RMED's ROE is +3.12%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, RMED is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RMED.
RMED vs APEN Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RMED is priced at $0.59, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas APEN's P/E ratio is -9.43. In terms of profitability, RMED's ROE is +3.12%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RMED is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs AVNS Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, AVNS has a market cap of 575.7M. Regarding current trading prices, RMED is priced at $0.59, while AVNS trades at $12.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas AVNS's P/E ratio is -1.51. In terms of profitability, RMED's ROE is +3.12%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, RMED is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs KIDS Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, KIDS has a market cap of 524.9M. Regarding current trading prices, RMED is priced at $0.59, while KIDS trades at $21.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas KIDS's P/E ratio is -12.04. In terms of profitability, RMED's ROE is +3.12%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RMED is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs AXGN Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, AXGN has a market cap of 497.3M. Regarding current trading prices, RMED is priced at $0.59, while AXGN trades at $10.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas AXGN's P/E ratio is -68.25. In terms of profitability, RMED's ROE is +3.12%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, RMED is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BVS Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BVS has a market cap of 443.9M. Regarding current trading prices, RMED is priced at $0.59, while BVS trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BVS's P/E ratio is -13.94. In terms of profitability, RMED's ROE is +3.12%, compared to BVS's ROE of -0.21%. Regarding short-term risk, RMED is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs CTKB Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, CTKB has a market cap of 435.7M. Regarding current trading prices, RMED is priced at $0.59, while CTKB trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas CTKB's P/E ratio is -38.22. In terms of profitability, RMED's ROE is +3.12%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, RMED is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs NPCE Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, NPCE has a market cap of 431.3M. Regarding current trading prices, RMED is priced at $0.59, while NPCE trades at $13.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas NPCE's P/E ratio is -16.04. In terms of profitability, RMED's ROE is +3.12%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, RMED is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs OFIX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, OFIX has a market cap of 429.8M. Regarding current trading prices, RMED is priced at $0.59, while OFIX trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas OFIX's P/E ratio is -2.96. In terms of profitability, RMED's ROE is +3.12%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, RMED is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SRDX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SRDX has a market cap of 420.4M. Regarding current trading prices, RMED is priced at $0.59, while SRDX trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SRDX's P/E ratio is -21.00. In terms of profitability, RMED's ROE is +3.12%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, RMED is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SENS Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SENS has a market cap of 399.2M. Regarding current trading prices, RMED is priced at $0.59, while SENS trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SENS's P/E ratio is -4.81. In terms of profitability, RMED's ROE is +3.12%, compared to SENS's ROE of -7.46%. Regarding short-term risk, RMED is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs CLPT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, CLPT has a market cap of 393.7M. Regarding current trading prices, RMED is priced at $0.59, while CLPT trades at $13.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas CLPT's P/E ratio is -18.33. In terms of profitability, RMED's ROE is +3.12%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, RMED is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs OM Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, OM has a market cap of 370.9M. Regarding current trading prices, RMED is priced at $0.59, while OM trades at $20.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas OM's P/E ratio is -0.73. In terms of profitability, RMED's ROE is +3.12%, compared to OM's ROE of -1.45%. Regarding short-term risk, RMED is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SMLR Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SMLR has a market cap of 367.8M. Regarding current trading prices, RMED is priced at $0.59, while SMLR trades at $32.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SMLR's P/E ratio is -15.13. In terms of profitability, RMED's ROE is +3.12%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, RMED is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs TMCI Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, TMCI has a market cap of 365.5M. Regarding current trading prices, RMED is priced at $0.59, while TMCI trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas TMCI's P/E ratio is -6.84. In terms of profitability, RMED's ROE is +3.12%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, RMED is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs NNOX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, NNOX has a market cap of 352.6M. Regarding current trading prices, RMED is priced at $0.59, while NNOX trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas NNOX's P/E ratio is -6.21. In terms of profitability, RMED's ROE is +3.12%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, RMED is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs VREX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, VREX has a market cap of 349.4M. Regarding current trading prices, RMED is priced at $0.59, while VREX trades at $8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas VREX's P/E ratio is -8.17. In terms of profitability, RMED's ROE is +3.12%, compared to VREX's ROE of -0.08%. Regarding short-term risk, RMED is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs PACB Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, PACB has a market cap of 339.1M. Regarding current trading prices, RMED is priced at $0.59, while PACB trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas PACB's P/E ratio is -0.41. In terms of profitability, RMED's ROE is +3.12%, compared to PACB's ROE of -1.70%. Regarding short-term risk, RMED is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs PTHL Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, PTHL has a market cap of 295.9M. Regarding current trading prices, RMED is priced at $0.59, while PTHL trades at $13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas PTHL's P/E ratio is -270.00. In terms of profitability, RMED's ROE is +3.12%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, RMED is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for RMED.
RMED vs CERS Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, CERS has a market cap of 288.7M. Regarding current trading prices, RMED is priced at $0.59, while CERS trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas CERS's P/E ratio is -15.10. In terms of profitability, RMED's ROE is +3.12%, compared to CERS's ROE of -0.35%. Regarding short-term risk, RMED is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs VMD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, VMD has a market cap of 265.6M. Regarding current trading prices, RMED is priced at $0.59, while VMD trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas VMD's P/E ratio is 22.40. In terms of profitability, RMED's ROE is +3.12%, compared to VMD's ROE of +0.10%. Regarding short-term risk, RMED is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ZIMV Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ZIMV has a market cap of 261.9M. Regarding current trading prices, RMED is priced at $0.59, while ZIMV trades at $9.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ZIMV's P/E ratio is -10.42. In terms of profitability, RMED's ROE is +3.12%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, RMED is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs MASS Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, MASS has a market cap of 249.2M. Regarding current trading prices, RMED is priced at $0.59, while MASS trades at $6.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas MASS's P/E ratio is -3.23. In terms of profitability, RMED's ROE is +3.12%, compared to MASS's ROE of -0.13%. Regarding short-term risk, RMED is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs CATX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, CATX has a market cap of 246.8M. Regarding current trading prices, RMED is priced at $0.59, while CATX trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas CATX's P/E ratio is -2.70. In terms of profitability, RMED's ROE is +3.12%, compared to CATX's ROE of -0.27%. Regarding short-term risk, RMED is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SNWV Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SNWV has a market cap of 238.3M. Regarding current trading prices, RMED is priced at $0.59, while SNWV trades at $27.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SNWV's P/E ratio is -4.47. In terms of profitability, RMED's ROE is +3.12%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, RMED is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs TCMD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, TCMD has a market cap of 233.4M. Regarding current trading prices, RMED is priced at $0.59, while TCMD trades at $10.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas TCMD's P/E ratio is 15.21. In terms of profitability, RMED's ROE is +3.12%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, RMED is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs MXCT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, MXCT has a market cap of 228.6M. Regarding current trading prices, RMED is priced at $0.59, while MXCT trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas MXCT's P/E ratio is -5.37. In terms of profitability, RMED's ROE is +3.12%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, RMED is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs NVRO Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RMED is priced at $0.59, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RMED's ROE is +3.12%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RMED is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs SGHT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, SGHT has a market cap of 217.1M. Regarding current trading prices, RMED is priced at $0.59, while SGHT trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas SGHT's P/E ratio is -4.29. In terms of profitability, RMED's ROE is +3.12%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, RMED is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs EYES Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, RMED is priced at $0.59, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas EYES's P/E ratio is N/A. In terms of profitability, RMED's ROE is +3.12%, compared to EYES's ROE of -0.26%. Regarding short-term risk, RMED is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs QTRX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, QTRX has a market cap of 208.5M. Regarding current trading prices, RMED is priced at $0.59, while QTRX trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas QTRX's P/E ratio is -4.33. In terms of profitability, RMED's ROE is +3.12%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, RMED is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs TLSI Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, TLSI has a market cap of 207.4M. Regarding current trading prices, RMED is priced at $0.59, while TLSI trades at $5.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas TLSI's P/E ratio is -4.98. In terms of profitability, RMED's ROE is +3.12%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, RMED is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BSGM Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BSGM has a market cap of 200.3M. Regarding current trading prices, RMED is priced at $0.59, while BSGM trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BSGM's P/E ratio is -13.85. In terms of profitability, RMED's ROE is +3.12%, compared to BSGM's ROE of +7.10%. Regarding short-term risk, RMED is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for RMED.
RMED vs BWAY Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BWAY has a market cap of 197.3M. Regarding current trading prices, RMED is priced at $0.59, while BWAY trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BWAY's P/E ratio is 47.50. In terms of profitability, RMED's ROE is +3.12%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, RMED is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs INGN Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, INGN has a market cap of 177.2M. Regarding current trading prices, RMED is priced at $0.59, while INGN trades at $6.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas INGN's P/E ratio is -5.73. In terms of profitability, RMED's ROE is +3.12%, compared to INGN's ROE of -0.15%. Regarding short-term risk, RMED is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ELMD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ELMD has a market cap of 176.5M. Regarding current trading prices, RMED is priced at $0.59, while ELMD trades at $21.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ELMD's P/E ratio is 25.99. In terms of profitability, RMED's ROE is +3.12%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, RMED is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs CVRX Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, CVRX has a market cap of 171.3M. Regarding current trading prices, RMED is priced at $0.59, while CVRX trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas CVRX's P/E ratio is -3.07. In terms of profitability, RMED's ROE is +3.12%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, RMED is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs AVR Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, AVR has a market cap of 169.6M. Regarding current trading prices, RMED is priced at $0.59, while AVR trades at $4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas AVR's P/E ratio is -2.38. In terms of profitability, RMED's ROE is +3.12%, compared to AVR's ROE of -2.92%. Regarding short-term risk, RMED is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs PROF Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, PROF has a market cap of 167.4M. Regarding current trading prices, RMED is priced at $0.59, while PROF trades at $5.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas PROF's P/E ratio is -4.60. In terms of profitability, RMED's ROE is +3.12%, compared to PROF's ROE of -0.70%. Regarding short-term risk, RMED is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ANIK Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ANIK has a market cap of 162.5M. Regarding current trading prices, RMED is priced at $0.59, while ANIK trades at $11.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ANIK's P/E ratio is -15.11. In terms of profitability, RMED's ROE is +3.12%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, RMED is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs RCEL Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, RCEL has a market cap of 161.5M. Regarding current trading prices, RMED is priced at $0.59, while RCEL trades at $6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas RCEL's P/E ratio is -2.79. In terms of profitability, RMED's ROE is +3.12%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, RMED is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs BDMD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, BDMD has a market cap of 158.6M. Regarding current trading prices, RMED is priced at $0.59, while BDMD trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas BDMD's P/E ratio is 9.06. In terms of profitability, RMED's ROE is +3.12%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, RMED is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMED.
RMED vs LNSR Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, LNSR has a market cap of 156.3M. Regarding current trading prices, RMED is priced at $0.59, while LNSR trades at $13.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas LNSR's P/E ratio is -2.70. In terms of profitability, RMED's ROE is +3.12%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, RMED is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs RPID Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, RPID has a market cap of 144.3M. Regarding current trading prices, RMED is priced at $0.59, while RPID trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas RPID's P/E ratio is -3.56. In terms of profitability, RMED's ROE is +3.12%, compared to RPID's ROE of -0.56%. Regarding short-term risk, RMED is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs LUCD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, LUCD has a market cap of 139.6M. Regarding current trading prices, RMED is priced at $0.59, while LUCD trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas LUCD's P/E ratio is -1.10. In terms of profitability, RMED's ROE is +3.12%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, RMED is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs LUNG Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, LUNG has a market cap of 127.6M. Regarding current trading prices, RMED is priced at $0.59, while LUNG trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas LUNG's P/E ratio is -2.20. In terms of profitability, RMED's ROE is +3.12%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, RMED is more volatile compared to LUNG. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs ICAD Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, ICAD has a market cap of 107.1M. Regarding current trading prices, RMED is priced at $0.59, while ICAD trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas ICAD's P/E ratio is -20.53. In terms of profitability, RMED's ROE is +3.12%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, RMED is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs MYO Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, MYO has a market cap of 106.7M. Regarding current trading prices, RMED is priced at $0.59, while MYO trades at $2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas MYO's P/E ratio is -21.18. In terms of profitability, RMED's ROE is +3.12%, compared to MYO's ROE of -0.36%. Regarding short-term risk, RMED is more volatile compared to MYO. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.
RMED vs OWLT Comparison
RMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMED stands at 3.8M. In comparison, OWLT has a market cap of 104.3M. Regarding current trading prices, RMED is priced at $0.59, while OWLT trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMED currently has a P/E ratio of -0.02, whereas OWLT's P/E ratio is -3.92. In terms of profitability, RMED's ROE is +3.12%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, RMED is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for RMED.